Literature DB >> 1695670

Immunoprotective Leishmania major synthetic T cell epitopes.

A Jardim1, J Alexander, H S Teh, D Ou, R W Olafson.   

Abstract

Using the predictive algorithm of Rothbard and Taylor (1988. EMBO J. 7:93) and the primary structure of gp63 (Button, L., and M.R. McMaster. 1988. J. Exp. Med. 167:724; Miller, R.A., S.G. Reed, and M. Parsons. 1990. Mol. Biochem. Parasitol. 39:267) we have been able to delineate the structures of a number of gp63 T-cell epitopes which stimulate the proliferation of CD4+ cells. One of these synthetic antigens, inoculated subcutaneously with adjuvant, was shown to specifically induce proliferation of the Th1 subset and provided immunoprotection against two species of Leishmania parasites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695670      PMCID: PMC2188333          DOI: 10.1084/jem.172.2.645

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  7 in total

1.  Characterization of the promastigote surface protease of Leishmania as a membrane-bound zinc endopeptidase.

Authors:  J Bouvier; C Bordier; H Vogel; R Reichelt; R Etges
Journal:  Mol Biochem Parasitol       Date:  1989-12       Impact factor: 1.759

2.  Surface acid proteinase (gp63) of Leishmania mexicana. A metalloenzyme capable of protecting liposome-encapsulated proteins from phagolysosomal degradation by macrophages.

Authors:  G Chaudhuri; M Chaudhuri; A Pan; K P Chang
Journal:  J Biol Chem       Date:  1989-05-05       Impact factor: 5.157

3.  Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.

Authors:  F Y Liew; A Singleton; E Cillari; J G Howard
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

4.  Leishmania gp63 molecule implicated in cellular adhesion lacks an Arg-Gly-Asp sequence.

Authors:  R A Miller; S G Reed; M Parsons
Journal:  Mol Biochem Parasitol       Date:  1990-03       Impact factor: 1.759

5.  Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.

Authors:  D G Russell; J Alexander
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

6.  Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection.

Authors:  F Y Liew; C Hale; J G Howard
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

7.  Molecular cloning of the major surface antigen of leishmania.

Authors:  L L Button; W R McMaster
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

  7 in total
  32 in total

Review 1.  Induction of T helper cell subsets.

Authors:  M Röcken; K M Müller; C Hauser
Journal:  Springer Semin Immunopathol       Date:  1992

2.  The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden.

Authors:  Harshita Satija Grover; Nicolas Blanchard; Federico Gonzalez; Shiao Chan; Ellen A Robey; Nilabh Shastri
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

3.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Differential regulation of Th1 and Th2 cells by p91-110 and p21-40 peptides of the 16-kD alpha-crystallin antigen of Mycobacterium tuberculosis.

Authors:  J N Agrewala; R J Wilkinson
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

5.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

6.  Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.

Authors:  E Handman; F M Symons; T M Baldwin; J M Curtis; J P Scheerlinck
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

7.  Human T-cell activation by 14- and 18-kilodalton nuclear proteins of Leishmania infantum.

Authors:  I Suffia; J F Quaranta; M C Eulalio; B Ferrua; P Marty; Y Le Fichoux; J Kubar
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

8.  Characterization of an I-E-restricted, gp63-specific, CD4-T-cell clone from Leishmania major-resistant C3H mice that secretes type 2 cytokines and exacerbates infection with L. major.

Authors:  Cynthia M Theodos; Robin V Morris; Jeanette V Bishop; Jeremy D Jones; W Robert McMaster; Richard G Titus
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

9.  Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection.

Authors:  D McMahon-Pratt; D Rodriguez; J R Rodriguez; Y Zhang; K Manson; C Bergman; L Rivas; J F Rodriguez; K L Lohman; N H Ruddle
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

Review 10.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.